Non-Small Cell Lung Cancer (NSCLC) - Metastatic

Recurrent or Metastatic (IIIB, IV)

1st line
- Squamous
  - IRB# 21821: A Phase Ib Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 510 (pNN Sotorasib) in Combination With AMG 404 in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation

- Non-squamous
  - IRB# 21826: KEAPSAKE - A Phase 2 Randomized, Multicenter, Double-Blind Study of the Glutaminase Inhibitor Telaglenastat With Pembrolizumab and chemotherapy in First-Line, Metastatic KEAP1/NRF2-Mutated, Non-squamous NSCLC

2nd/3rd line

- CROSS-DISEASE TRIALS:
  - IRB# 18084: S1609 (DART)
  - IRB# 19992: MATCH - Molecular Analysis for Therapy Choice (MATCH)
  - IRB# 21325: RGX-104

- CodeBreak 101: A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 510 (pNN Sotorasib) in Combination With AMG 404 in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation

- IRB# 21772: S1900E: A Phase II Study of AMG 510 in Participants with Previously Treated Stage IV or Recurrent KRAS G12C Mutated Non-Squamous Non-Small Cell Lung Cancer (ECOG-ACRIN LUNG-MAP SUBSTUDY)

- IRB# 21770: EAS191: A Randomized Phase II Trial of Cabozantinib and Cabozantinib plus Nivolumab Versus Standard Chemotherapy in Patients with Previously Treated NonSquamous NSCLC

- IRB# 21589: S1900E: A Phase II STUDY OF Selperecatinib (LOXO-292) IN PATIENTS WITH RET FUSION POSITIVE STAGE IV OR RECURRENT NON-SMALL CELL LUNG CANCER (LUNG-MAP SUBSTUDY)

Key
- Open for Enrollment
- In Development
- Enrollment on Hold

http://www.ohsu.edu/research/rda/so/knight.php